Vericel (NASDAQ:VCEL) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Vericel Co. (NASDAQ:VCEL)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $49.27 and traded as high as $59.43. Vericel shares last traded at $58.08, with a volume of 394,963 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VCEL. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Friday, November 8th. Stephens raised shares of Vericel to a “strong-buy” rating in a research note on Monday, December 2nd. Truist Financial increased their target price on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, BTIG Research boosted their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vericel presently has an average rating of “Buy” and an average target price of $61.14.

Vericel Stock Up 2.5 %

The stock has a 50 day simple moving average of $55.40 and a 200 day simple moving average of $49.43. The company has a market cap of $2.94 billion, a price-to-earnings ratio of 992.33 and a beta of 1.72.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. As a group, equities research analysts expect that Vericel Co. will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling at Vericel

In related news, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the sale, the insider now owns 58,371 shares in the company, valued at approximately $3,427,545.12. The trade was a 14.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the transaction, the director now owns 11,000 shares in the company, valued at $454,960. This trade represents a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,433 shares of company stock valued at $1,855,275 in the last ninety days. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Vericel by 1.6% during the 2nd quarter. Rhumbline Advisers now owns 144,572 shares of the biotechnology company’s stock valued at $6,633,000 after acquiring an additional 2,297 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Vericel by 51.5% in the 2nd quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company’s stock valued at $28,039,000 after buying an additional 207,714 shares during the period. Arizona State Retirement System grew its position in shares of Vericel by 3.3% during the 2nd quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock valued at $590,000 after buying an additional 406 shares during the last quarter. PFG Investments LLC raised its stake in Vericel by 6.2% during the second quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock worth $314,000 after acquiring an additional 400 shares during the period. Finally, State of New Jersey Common Pension Fund D acquired a new position in Vericel in the second quarter valued at approximately $1,826,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.